Bayer and Oxford Genome Sciences form breast cancer marker pact:
This article was originally published in Clinica
Bayer HealthCare has teamed up with the UK proteomics technology company, Oxford Genome Sciences (OGeS), to evaluate new biomarkers for breast cancer. OGeS will assess the candidate biomarkers - previously identified by Bayer - that may have important applications in the diagnosis and prognosis of the disease. The evaluation will be performed using OGeS' proteomics platform, in conjunction with its Oxford Genome Anatomy Project (OGAP), which is claimed to be the "world's largest proteomics database". Under the agreement, OGeS will receive programme funding from Bayer, which will also make performance-related payments on the achievement of certain milestones.